meetings

DR. GUTMANN:  So, we're off to a great start, and now, we're turning our attention to discussing directly, questions of individual privacy and the public good, and I emphasize both, individual privacy and the public good, as they relate to whole genome sequencing, and we've already had hints of this issue in our earlier session.

DR. GUTMANN:  Good morning, everybody.  I'm Amy Gutmann.  I am Chair of the Presidential Commission for the Study of Bioethical Issues and President of the University of Pennsylvania, and my Vice Chair, Jim Wagner, who is President of Emory University will lead off this morning's session, but let me just do a few preliminary things, if I may.

            DR. GUTMANN:  So, thank you all, first, for your presentations and second, for participating in a roundtable, and square roundtable, yes, and if we have -- do we have Dan's slide about attitudes towards privacy that we could put up, so, why don't we -- because we had asked Dan about what they found.  So, Dan, why don't you just say a few -- just explain what you found, just because I'm going to ask a question about privacy to everybody.

            DR. MASYS:  Okay.

            DR. GUTMANN:  Go ahead.

DR. GUTMANN:  Sorry, I turned it off. We're now going to switch gears to focus on law enforcement use and access to genetic information, and to do so I first would like to welcome Melissa Mourges.  Thank you very much.

            Ms. Mourges is an Assistant District Attorney and the Chief of the Forensic Sciences Cold Case Unit of the New York County DA's Office.

DR. WAGNER:  Let's go ahead and collect some thoughts for a final session here.  Christine.  I got you.  Actually I shouldn't have been yelling at you because I don't see Dan or Nelson here.   Oh, we got Nelson.  Why don't we - Dan is so wonderfully perceptive.  He can jump in halfway through this and he is good like that, so let's go ahead and get started.

            Oh, here's Dan.  Perfect, perfect timing.  Perfect timing.

DR. GUTMANN:  Yes, we are going to quickly switch speakers.  So in this discussion we will focus on current clinical and research experience with advancing neuroscience, and I'm really delighted to have Dr. Bernie Lo with us who will introduce us to ethical issues in clinical care and Dr. Anthony Wagner who will be with us in a moment who will bring us up to date on recent scientific advances in neuroscience.

            DR. WAGNER:  Well, good afternoon.  Welcome back, to our guests.  This Session 3 is also on the privacy issues, control, access and human genome sequence data.

            I remind the folks joining us, that if you develop questions during these presentations, or as we are asking questions, the staff can help you locate a card to get that question up to the front, and we're very happy to interject your thoughts and comments.  This is a learning period for the Commission.

            DR. WAGNER:  I think we can move right into our first session.

            We have the privilege of hearing from these three, who I promise to be very interesting speakers, going to talk not only about personal experiences with whole genome sequencing and its effect on families, but also, we are going to receive this morning, a brief update on the current state of human genome sequencing, and we hope all will discuss some of the ethical issues that are facing us.

            DR. GUTMANN:  First of all, welcome, everybody and good morning. 

            I am Amy Gutmann and I am Chair of the Presidential Commission for the Study of Bioethics, and I am also President of the University of Pennsylvania, and on behalf of myself and our terrific Vice Chair, Jim Wagner, who is President of Emory University, I'd like to welcome you to the first day of our deliberations, and I also am delighted that we're in San Francisco, and I have to give a very special thanks to Dr. Stephen Hauser, for enabling us to be at the UCSF Campus.

Amy Gutmann:  Okay. Welcome back.  This is the final session of this meeting and it’s important for this session for us to go back to the fundamental question put to the commission.